No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
IART240621C50000
- 1.72
- 0.000.00%
15min DelayTrading Feb 15 15:34 ET
0.00High0.00Low
0.00Open1.72Pre Close0 Volume92 Open Interest50.00Strike Price0.00Turnover854.96%IV77.82%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry1.72Extrinsic Value100Contract SizeAmericanOptions Type0.2361Delta0.0194Gamma16.91Leverage Ratio-1.5203Theta0.0002Rho3.99Eff Leverage0.0057Vega
Intraday
- 5D
- Daily
News
S&P 400 Rejig: HTZ, PENN to Exit Index; Illumina Moves Down From S&P 500
KKR & Co, CrowdStrike, GoDaddy to Join S&P 500 Index on June 24
KKR (KKR), CrowdStrike (CRWD), and GoDaddy (GDDY) will replace Robert Half (RHI), Comerica (CMA), and Illumina (ILMN) in the S&P 500 index from June 24, S&P Dow Jones Indices said on Friday. Illumina
$318.8 Mn Dural Adhesive Agent for Surgical Market - Global and Regional Analysis and Forecasts, 2024-2034 Featuring Prominent Players - Integra LifeSciences, Covidien, Baxter, Johnson & Johnson - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Dural Adhesive Agent for Surgical Market - A Global and Regional Analysis: Focus on Application, Type, Form, and Country-Level Analysis - Analysis and Forecast, 2024-2034
$1.5M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed mostly higher on Friday, there were a few notable insider trades.When insiders purchase shares, it indicates their confidence in the company's prospects or that they view t
What Does Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Share Price Indicate?
Integra Lifesciences(IART.US) Officer Buys US$1.5 Million in Common Stock
$Integra Lifesciences(IART.US)$ Officer ESSIG STUART purchased 52,641 shares of common stock on May 23, 2024 at an average price of $28.4945 for a total value of $1.5 million.Source: Announcement What
Comments
EPS growth doesn't align with share price, indicating it may not reflect business performance or growth expectations may have been high. Integra LifeSciences Holdings' performance led to a 3% annual loss for shareholders over five years. Investors should note 3 warning signs.
While Shareholders of Integra LifeSciences Holdings (NASDAQ:IART) Are in the Red Over the Last Three Years, Underlying Earnings Have Actually GrownInsider transactions suggest a positive outlook for Integra LifeSciences Holdings, with insiders net buying the stock. The level of insider ownership indicates a reasonable degree of alignment with shareholder interests.
1
Integra LifeSciences Holdings trades at a low price, suggesting a buying opportunity. Higher cash flow is expected, potentially boosting share valuation. The positive outlook seems not fully factored into the share price, indicating it's not too late to buy IART.
Analysts insist that Integra LifeSciences' robust future growth justifies its high P/E, negating any expectations of a significant share price drop due to low odds of earnings deterioration.
The Acclarent acquisition provides Integra LifeSciences the chance to scale and seize leadership in the ENT device segment, enriching its innovative portfolio and providing shareholder value. In tandem with Integra's neurosurgery segment, it signifies a strategic move that will enhance innovation across ENT and other CSS technologies.
Read more